SNS812: meta-analysis of COVID-19 studies

Meta-analysis1 study · 90 patientsc19early.org

SNS812 for COVID-19

Serious outcome risk
SNS812
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)52%
RCTs (1)52%
Early (1)52%
00.511.5+
← SNS812
reduces risk
Increased
risk →
October 2026

SNS812 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.0022
All studies52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.002200.511.52+
Rotate screen for more detailsIncrease width for more details
← SNS812
reduces risk
SNS812
increases risk →
October 2026

SNS812 COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.0022
All studies52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.002200.511.52+
Rotate screen for more detailsIncrease width for more details
← SNS812
reduces risk
SNS812
increases risk →
October 2026

SNS812 COVID-19 viral clearance results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment14%0.86 · 0.75–0.9945 (n)44 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.04
All studies14%0.86 · 0.75–0.9945 (n)44 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.0400.511.52+
Rotate screen for more detailsIncrease width for more details
← SNS812
reduces risk
SNS812
increases risk →
October 2026

SNS812 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.0022
All studies52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.002200.511.52+
Rotate screen for more detailsIncrease width for more details
← SNS812
reduces risk
SNS812
increases risk →
October 2026

SNS812 COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Early treatment52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.0022
All studies52%0.48 · 0.30–0.7745 (n)45 (n)52% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.002200.511.52+
Rotate screen for more detailsIncrease width for more details
← SNS812
reduces risk
SNS812
increases risk →
October 2026

SNS812 COVID-19 outcomes